Nykode Therapeutics ASA
- Country
- 🇳🇴Norway
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 173
- Market Cap
- $207.4M
- Website
- http://www.nykode.com
Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.
- Conditions
- Interventions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Nykode Therapeutics ASA
- Target Recruit Count
- 130
- Registration Number
- NCT06099418
- Locations
- 🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸Parkview Research Center, Fort Wayne, Indiana, United States
🇺🇸Hoag Memorial Hospital, Newport Beach, California, United States
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Nykode Therapeutics ASA
- Target Recruit Count
- 51
- Registration Number
- NCT06016920
- Locations
- 🇫🇷
CRLC Val d'Aurelle - Institut de Recherche en Cancerologie de Montpellier (IRCM), Montpellier, France
🇨🇿Fakultni nemocnice Olomouc, Olomuoc, Olomouc, Czechia
🇫🇷Hospices Civils De Lyon, Lyon, France
A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers
- Conditions
- Interventions
- First Posted Date
- 2021-10-06
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Nykode Therapeutics ASA
- Target Recruit Count
- 68
- Registration Number
- NCT05069623
- Locations
- 🇳🇴
Oslo University Hospital Ullevål Sykehus, Dept. Infection Diseases, Oslo, Norway
🇳🇴Haukeland University Hospital, Klinisk Forskningspost, Bergen, Norway
Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Nykode Therapeutics ASA
- Target Recruit Count
- 26
- Registration Number
- NCT05018273
- Locations
- 🇪🇸
Hospital Universitario Vall d'Hebron, Barcelona, Spain
🇺🇸Yale Cancer Institute, New Haven, Connecticut, United States
🇺🇸MD Andersson, Houston, Texas, United States
Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-05-28
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Nykode Therapeutics ASA
- Target Recruit Count
- 52
- Registration Number
- NCT04405349
- Locations
- 🇧🇪
Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
🇧🇬University Multiprofile Hospital For Active Treatment Sofiamed, Sofia, Bulgaria
🇵🇱Jagielońskie Centum Innowacji, Centrum Badań Klinicznych JCI, Kraków, Poland
A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-06-07
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Nykode Therapeutics ASA
- Target Recruit Count
- 41
- Registration Number
- NCT03548467
- Locations
- 🇩🇪
University Hospital Heidelberg, NCT, Im Neuenheimer Feld 460, Heidelberg, Germany
🇩🇪Universitätsmedizin Mannheim, Mannheim, Germany
🇩🇪Krankenhaus Nordwest gGmbH, Frankfurt, Germany
An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)
- Conditions
- Interventions
- First Posted Date
- 2015-08-20
- Last Posted Date
- 2022-07-13
- Lead Sponsor
- Nykode Therapeutics ASA
- Target Recruit Count
- 34
- Registration Number
- NCT02529930
- Locations
- 🇩🇪
Universitätsklinikum Hamburg-Eppendorf, Hamburg, Lower Saxony, Germany
🇩🇪Medical School Hanover, Hannover, Lower Saxony, Germany
🇩🇪IZD Institut für Zytologie und Dysplasie, Hannover, Niedersachsen, Germany